GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

Tempus AI TEM · USD

Health Care · US listing · 🇺🇸 United States

Compare

54.04

-9.34%

Close of 20 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Tempus AI — daily TEM Delayed
Market value
$9.42bn
Last close × shares
Volume
7.4m
Shares, 20 Nov 2026

About Tempus AI

From its filings with the US Securities and Exchange Commission

SEC filings

Tempus AI is based in Chicago, Illinois and is incorporated in Nevada. Its shares trade on Nasdaq under the ticker TEM. The SEC classifies its business as computer programming, data processing, etc.. In the fiscal year to 31 December 2025, it reported revenue of $1.27bn and a net loss of $245.0m. At that date it held total assets of $2.27bn and shareholders' equity of $491.3m.

In its own words

We endeavor to unlock the true power of precision medicine by creating Intelligent Diagnostics through the practical application of artificial intelligence, or AI, in healthcare. Intelligent Diagnostics use AI, including generative and agentic AI, to make laboratory tests more accurate, tailored, and personal. We make tests intelligent by connecting laboratory results to a patient’s own clinical data, thereby personalizing the results. Our novel insight was realizing that all laboratory test results, genomic or otherwise, could be contextualized for a specific patient based upon that patient’s unique characteristics, and technology could therefore guide therapy selection and treatment decisions to allow each patient to progress on their own unique path. The drugs recommended, the clinical trials explored, the care pathways evaluated, and the adverse events considered—all have the potential to be refined and enhanced when test results are connected to a patient’s personal profile, enabling the right patient to be routed to the right therapy at the right time.

To accomplish this, we built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Our proprietary technology has allowed us to amass what we consider to be one of the largest libraries of clinical and molecular oncology data in the world.

Quoted from its 10-K, filed 24 Feb 2026. Read the filing on SEC.gov ↗

More about Tempus AI →

Latest on Tempus AI

Our reporting

Next results

23 Feb 2027

Due on 23 Feb 2027. Analysts expect earnings of 0.06 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Tempus AI's ticker?

Tempus AI trades as TEM on its US listing, under ISIN US88023B1035.

What was Tempus AI's last closing price?

54.04 on 20 Nov 2026. The figure is in USD and is never converted.

When does Tempus AI next report results?

Results are expected on 23 Feb 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.